<a href="https://www.fiercebiotech.com/biotech/lilly-licenses-alzecure-alzheimers-asset-1b-biobucks" hreflang="en">Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal</a>
Eli Lilly has entered a licensing agreement with AlzeCure Pharma for a gamma-secretase modulator treatment for Alzheimer's disease, potentially worth up to $1 billion. The treatment aims to reduce harmful amyloid-beta protein production and may also serve as a preventive measure against Alzheimer's development.
Eli Lilly's recent licensing deal with AlzeCure Pharma highlights a significant opportunity in the Alzheimer's therapeutic landscape, with the potential to tap into a market projected to increase eightfold by 2034. For someone tracking healthtech and biotech investment signals, this move underscores the strategic importance of partnerships in advancing Alzheimer's treatments and the potential high value of successful drug commercialization in this domain.